ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs MXN
16.6998
0.00%
Brent Oil
81.965
0.00%
Bitcoin
69,210.00
0.99%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. AC Immune SA (ACIU)

  7. AC Immune SA (ACIU) Noticias

ACIU

AC Immune (ACIU)

AC Immune SA
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ACIU
FechaHoraFuenteTítuloSímboloCompañía
21/05/202407:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ACIUAC Immune SA
16/05/202413:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACIUAC Immune SA
09/02/202415:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACIUAC Immune SA
03/01/202407:10GlobeNewswire Inc.AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseasesNASDAQ:ACIUAC Immune SA
15/12/202316:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ACIUAC Immune SA
27/06/202312:30AllPennyStocks.comBiotech Pops On FDA Fast Track DesignationNASDAQ:ACIUAC Immune SA
27/06/202307:23Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ACIUAC Immune SA
27/06/202307:11Dow Jones NewsAC Immunity Shares Jump 18% After Fast-Track Designation on Alzheimer's TreatmentNASDAQ:ACIUAC Immune SA
16/03/202306:32Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:ACIUAC Immune SA
10/02/202315:02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ACIUAC Immune SA
01/12/202207:45TipRanksH.C. Wainwright Keeps Their Buy Rating on AC Immune SA (ACIU)NASDAQ:ACIUAC Immune SA
01/11/202223:45TipRanksSVB Securities Sticks to Its Buy Rating for AC Immune SA (ACIU)NASDAQ:ACIUAC Immune SA
31/10/202205:15TipRanksAC Immune SA (ACIU) Receives a Buy from H.C. WainwrightNASDAQ:ACIUAC Immune SA
28/08/202222:15TipRanksSVB Securities Keeps Their Buy Rating on AC Immune SA (ACIU)NASDAQ:ACIUAC Immune SA
11/07/202207:40TipRanksSVB Securities Thinks AC Immune SA’s Stock is Going to RecoverNASDAQ:ACIUAC Immune SA
19/06/202202:05TipRanksH.C. Wainwright Sticks to Their Buy Rating for AC Immune SA (ACIU)NASDAQ:ACIUAC Immune SA
16/06/202205:57Dow Jones NewsAC Immune Shares Fall Premarket on Alzheimer's Study MissNASDAQ:ACIUAC Immune SA
29/04/202205:26TipRanksH.C. Wainwright Thinks AC Immune SA’s Stock is Going to RecoverNASDAQ:ACIUAC Immune SA
21/12/202101:11TipRanksLeerink Partners Sticks to Its Buy Rating for AC Immune SA (ACIU)NASDAQ:ACIUAC Immune SA
12/11/202108:44Dow Jones NewsAC Immune Sees Positive Data in Trial for Alzheimer's Disease TreatmentNASDAQ:ACIUAC Immune SA
31/08/202109:55Dow Jones NewsAC Immune Shares Rally on Renewed Hope for Semorinemab in Alzheimer'sNASDAQ:ACIUAC Immune SA
31/08/202107:33Dow Jones NewsAC Immune: Semorinemab Meets Co-Primary Endpoint in Alzheimer's DiseaseNASDAQ:ACIUAC Immune SA
05/08/202116:16Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ACIUAC Immune SA
27/07/202107:00GlobeNewswire Inc.AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseasesNASDAQ:ACIUAC Immune SA
06/05/202105:07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ACIUAC Immune SA
23/11/202015:31Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:ACIUAC Immune SA
23/10/202016:24Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:ACIUAC Immune SA
23/09/202012:30Dow Jones NewsAC Immune Down 43%; Semorinemab Didn't Meet Endpoint in Early Alzheimer's DiseaseNASDAQ:ACIUAC Immune SA
23/09/202008:23Dow Jones NewsAC Immune Down; Semorinemab Didn't Meet Efficacy Endpoint in Early Alzheimer's DiseaseNASDAQ:ACIUAC Immune SA
23/09/202006:59Dow Jones NewsAC Immune: Semorinemab Didn't Meet Co-Primary Efficacy Endpoint in Early Alzheimer's DiseaseNASDAQ:ACIUAC Immune SA
 Showing the most relevant articles for your search:NASDAQ:ACIU

Su Consulta Reciente

BIT
I06753
Intesa Sanpaolo
ASX
88EN
88 Energy
COIN
LSSUST
Lossless Token
DOWI
DJTLSV
DJ US Relative Value
NYSE
MZF
ASE
ELHAB1
Elvalhalcor
TSX
ESG
Invesco S & P 500 ESG In...
EU
INGTG
INGTG
TG
3C1
Carbios
LSE
0GOX
Polytec
NASDAQ
ABAJEXX
Hsbc Bank Usa Na Capped ...
USOTC
PGEZF
Stillwater Critical Mine... (QB)
LSE
80AQ
Natwest.m 25
AMEX
OARK
YieldMax Innovation Opti...
BOV
LILY34M
Lilly Drn
NASDAQ
AAWXFXX
HSBC USA Inc Dual Direct...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados